Krypto Genetics LK

Belkins
Krypto Genetics (PVT) LTD. is a leading supplier for R&D sector specialized in the areas of Life sciences, Genetics, Biotechnology, Molecular Biology and Molecular Diagnostics. Our Mission To provide the most cost effective solutions for Sri Lankan Scientists to face the challenges imposed on them due to unavoidable policy and procedure gaps prevailing in the system very successfully and to achieve excellence in their research activities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

news image

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

news image

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More

MEDICAL

DEBIOPHARM ANNOUNCES FIRST PATIENT DOSED IN INVESTIGATOR-INITIATED, RANDOMIZED PHASE II, OPEN-LABEL CLINICAL TRIAL FOR ITS ANTIVIRAL ALISPORIVIR

Debiopharm | January 18, 2021

news image

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...

Read More

CELL AND GENE THERAPY

INTEGRAL MOLECULAR INTRODUCES TRANSGENE PROTEIN ENGINEERING PLATFORM TO ADDRESS GENE THERAPY CHALLENGES

Integral Molecular | August 02, 2021

news image

Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements. GeneCanvas can achieve 10 to 100 fold increases in gene activity by improving transgene protein expression, trafficking, stability, and function. These enhancements will ultimately result in better efficacy, smaller doses, and improved safety for patients. The GeneCanvas...

Read More
news image

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More
news image

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More
news image

MEDICAL

DEBIOPHARM ANNOUNCES FIRST PATIENT DOSED IN INVESTIGATOR-INITIATED, RANDOMIZED PHASE II, OPEN-LABEL CLINICAL TRIAL FOR ITS ANTIVIRAL ALISPORIVIR

Debiopharm | January 18, 2021

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...

Read More
news image

CELL AND GENE THERAPY

INTEGRAL MOLECULAR INTRODUCES TRANSGENE PROTEIN ENGINEERING PLATFORM TO ADDRESS GENE THERAPY CHALLENGES

Integral Molecular | August 02, 2021

Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements. GeneCanvas can achieve 10 to 100 fold increases in gene activity by improving transgene protein expression, trafficking, stability, and function. These enhancements will ultimately result in better efficacy, smaller doses, and improved safety for patients. The GeneCanvas...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us